What's New in Canada?



Release Date


Health Canada approves fast-acting mealtime insulin, Fiasp®, for children with diabetes



Novo Nordisk Canada Inc. recognized as one of Greater Toronto's Top Employers for 2020



OZEMPIC® is now listed on the Quebec provincial formulary for adults living with type 2 diabetes



OZEMPIC® is now listed on the Ontario provincial formulary for adults living with type 2 diabetes



Novo Nordisk Canada announces appointment of new president



New international study: The hidden burden of diabetes on family members revealed



OZEMPIC® is now listed on the Alberta provincial formulary for adults living with type 2 diabetes



ESPEROCT® is now approved in Canada for the Treatment of Hemophilia A in both Children and Adults



Xultophy® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes



Health Canada approves TRESIBA® for children with Type 1 diabetes



Government of Quebec provides adults living with diabetes mellitus access to ultra-long-acting insulin, TRESIBA®



Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus



Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo® in real-world evidence study



Major Partnership set to tackle Diabetes; One of Alberta’s most significant health concerns



Xultophy® approved in Canada for the treatment of adults with type 2 diabetes



Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec



Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada



Ozempic® now available for Canadians with type 2 diabetes



Ozempic® approved in Canada for the treatment of adults with type 2 diabetes



Health Canada approves Victoza® as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.



Striking blood sugar balance is critical for Canadians living with diabetes



Health Canada approves Tresiba®, a new basal insulin for type 1 and 2 diabetes



Media Advisory - IndyCar Racer Charlie Kimball doesn't let his diabetes take the driver's seat



Important safety information regarding NovoPen Echo® and NovoPen® 5.



New fast-acting mealtime insulin, Fiasp®, now approved and available in Canada for the treatment of diabetes



Vancouver joins with global cities to push for action against urban diabetes



Study finds Victoza® significantly reduced the risk of heart attack and stroke in people with type 2 diabetes.



Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart).



Saxenda® demonstrated similar efficacy and safety profile across obesity severity stages.



Global Cities Changing Diabetes Initiative Comes to Vancouver.



While obesity rates differ among ethnic groups; data shows similar weight loss results using Saxenda®.



Novo Nordisk Canada secures place on Canada’s Top 100 Employer listing.



Novo Nordisk announced the availability of Saxenda® (liraglutide) in Canada, the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for chronic weight management in combination with diet and exercise.



Health Canada and Novo Nordisk Canada review new safety information for repaglinide.



Appointment Notice - Novo Nordisk Canada Inc.



The Results are in… Team Novo Nordisk caps off another successful Canadian Visit at Tour de Beauce



Novo Nordisk receives Health Canada approval for Saxenda® (liraglutide) for the treatment of chronic weight management



Athlete with type 1 diabetes to finish 7500km run across
Canada in Vancouver on world diabetes day



Novo Nordisk Canada is pleased to be included in the
"Canada's Top 100 Employers" listing for 2015 announced in a special magazine co-published in the national edition of The Globe and Mail this morning.



Novo Nordisk Marks 90 Years of Innovating Diabetes CareDenmark's Crown Prince Couple Help Celebrate Canadian, Danish Partnership, Marking Novo Nordisk's 30 Years in Canada



Québec Becomes First Province to Add Victoza® to the Drug Benefit Formulary* for the Treatment of Type 2 Diabetes



Team Novo Nordisk, the world's first all-diabetes professional cycling team, races in Tour de Beauce



Global study: 1 in 4 Canadians with diabetes experience significant emotional distress, 1 in 6 report feelings of discrimination due to their disease



Canadian biotech industry recognizes top performers



Families carry a major burden of the diabetes pandemic, according to new results from global study



Global survey reveals more than a quarter of Canadians with type 2 diabetes do not take insulin as prescribed and one third are experiencing events of low blood sugar frequently.